Grace Therapeutics, Inc. Proceeds from Stock Options Exercised
Grace Therapeutics, Inc. (GRCE) reported Proceeds from Stock Options Exercised of $0 for the 12-month period ending 2025-03-31, per its 10-K filed 2025-06-23.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2025-06-23
- Grace Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2025-03-31 was $0.00.
- Grace Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2024-12-31 was $0.00.
- Grace Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2024-03-31 was $0.00.
- Grace Therapeutics, Inc. proceeds from stock options exercised for the quarter ending 2023-12-31 was $0.00.
- Grace Therapeutics, Inc. proceeds from stock options exercised for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- Grace Therapeutics, Inc. proceeds from stock options exercised for fiscal 2024 was $21.00K.
- Grace Therapeutics, Inc. proceeds from stock options exercised for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- Grace Therapeutics, Inc. proceeds from stock options exercised for fiscal 2021 was $118.00K, a 162.22% increase from fiscal 2020.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2025-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $0.00 derived: sum of 2 quarters · filed 2025-06-23 | $0.00 10-K · filed 2025-06-23 | |
| 2024-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $0.00 10-Q · filed 2025-02-13 | ||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-13 | |||
| 2024-03-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-23 | $0.00 derived: sum of 2 quarters · filed 2025-06-23 | $21.00K 10-K · filed 2025-06-23 | |
| 2023-12-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-02-13 | $21.00K 10-Q · filed 2025-02-13 | ||
| 2023-09-30 | $21.00K 10-Q · filed 2024-11-13 | |||
| 2022-03-31 | $0.00 10-K · filed 2022-06-21 | |||
| 2021-03-31 | $118.00K 10-K · filed 2022-06-21 | |||
| 2020-03-31 | $45.00K 10-K · filed 2020-06-29 | $78.00K derived: sum of 2 quarters · filed 2021-02-09 | $91.00K derived: sum of 3 quarters · filed 2021-02-09 | $45.00K 10-K · filed 2021-06-22 |
| 2019-12-31 | $33.00K 10-Q · filed 2021-02-09 | $46.00K derived: sum of 2 quarters · filed 2021-02-09 | $45.00K 10-Q · filed 2021-02-09 | |
| 2019-09-30 | $13.00K 10-Q · filed 2020-11-16 | $13.00K 10-Q · filed 2020-11-16 | ||
| 2019-03-31 | $2.00K 10-K · filed 2020-06-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |